TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05640102: Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Sponsor: BeiGene · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 111 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,261,600

Rescue Site Savings

+$830,000

Unlock Full NCT05640102 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05640102 Rescue Dossier →